Amir M. Alhajjat

Amir M. Alhajjat

Auto-generated profile, based on publicly available information

Amir M. Alhajjat

Chicago Institute for Fetal Health, Ann & Robert H. Lurie Children's Hospital Chicago Illinois USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2012 in The American Surgeon™
Verified
Journal Article
Open access
PDF file
AAAmir Alhajjat
Amir Alhajjat
GKGopal C. Kowdley
Gopal C. Kowdley

14 June 2024 in Prenatal Diagnosis
Verified
Journal Article
Closed access
SPSteven T. Papastefan
Steven T. Papastefan
AAAmir M. Alhajjat
Amir M. Alhajjat
KOKatherine C. Ott
Katherine C. Ott
DLDaniel R. Liesman
Daniel R. Liesman
MLMorgan M. Langereis
Morgan M. Langereis
ASAimen F. Shaaban
Aimen F. Shaaban

3 September 2026 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
SBStephanie F. Brierley
Stephanie F. Brierley
BOBrielle Ochoa
Brielle Ochoa
AAAmir Alhajjat
Amir Alhajjat
EBEmily Byrd
Emily Byrd
SCStephanie D. Chao
Stephanie D. Chao
BPBenjamin E. Padilla
Benjamin E. Padilla

3 May 2018 in Current Stem Cell Reports
Verified
Journal Article
Open access
PDF file
AAAmir M. Alhajjat
Amir M. Alhajjat
ASAimen F. Shaaban
Aimen F. Shaaban
Purpose of Review In utero hematopoietic cellular transplantation (IUHCT) is a promising intervention for the non-toxic treatment of congenital disease that hinges on the assumption of fetal immunologic immaturity and an inability to reject a hematopoietic allograft. However, clinical IUCHT has failed except in cases where the fetus is severely immunocompromised. The current review examines recent studies of engraftment barriers stemming from either the fetal or maternal immune system. Recent Findings New reports have illuminated roles for maternal humoral and cellular immunity and fetal innate cellular immunity in the resistance to allogeneic IUHCT. These experimental findings have inspired new approaches to overcome these barriers. Despite these advances, postulates regarding a maternal immune barrier to IUHCT provide an inadequate explanation for the well-documented clinical success only in the treatment of fetal immunodeficiency with normal maternal immunity. Summary Characterization of the maternal and fetal immune response to allogeneic IUHCT provides new insight into the complexity of prenatal tolerance. Future work in this area should aim to provide a unifying explanation for the observed patterns of success and failure with clinical IUHCT.

29 June 2026 in Pediatric Pulmonology
Verified
Journal Article
Closed access
DLDaniel R. Liesman
Daniel R. Liesman
CRCatherine R. Redden
Catherine R. Redden
RWRyan Willey
Ryan Willey
NONkechinyelum Ogu
Nkechinyelum Ogu
ADAmanda Dicks
Amanda Dicks
AAAmir M. Alhajjat
Amir M. Alhajjat